Reeve Waud’s Healthcare Services Ecosystem: A Template for Clinical Trial Investment

Nordic Capital and Riverside Partners’ clinical trial management system investments signal broader private equity interest in research technology infrastructure, but experienced healthcare investors recognize these opportunities as part of larger ecosystem plays rather than standalone software acquisitions. Reeve Waud’s systematic approach to building integrated healthcare services platforms provides a framework for understanding why clinical trial technology investments achieve optimal returns when positioned within comprehensive healthcare service ecosystems.

Waud Capital Partners has developed this ecosystem investment strategy across three decades of healthcare platform development, creating integrated service networks that address multiple touchpoints within specific healthcare segments. Reeve Waud’s methodology offers a template for clinical trial investment that extends beyond individual software solutions to encompass the entire research service infrastructure.

The Ecosystem Approach

Recent Waud Capital platform development demonstrates how Reeve Waud’s team constructs healthcare ecosystems that create competitive advantages through integration. The firm has formed Altocare, described as “a newly formed home care holding company of Waud Capital Partners” that acquired MedTec Healthcare to join with Senior Helpers, “creating a comprehensive home care platform that focuses on serving private-pay and Medicaid-supported clients.”

This consolidation strategy addresses multiple aspects of healthcare delivery rather than focusing on single-point solutions. According to Executive Chairman Steve Jakubcanin, “This acquisition represents a significant step in our vision to create a leading home care platform that delivers best-in-class care.”

Clinical trial investment benefits from similar ecosystem thinking. Rather than acquiring standalone trial management software, Reeve Waud’s approach suggests combining patient recruitment platforms, data management systems, regulatory compliance tools, and site coordination services into integrated clinical research ecosystems that serve pharmaceutical companies’ comprehensive needs.

Mission-Critical Software Focus

Waud Capital targets “mission-critical software with clear value propositions that help companies operate more effectively,” particularly solutions with “attractive, recurring revenue business models in niches like vertical application software, integrated payments, knowledge technology, and healthcare IT.”. Clinical trial management systems exhibit exactly these characteristics while supporting broader research service ecosystems.

Reeve Waud’s investment in Integrated Practice Solutions demonstrates how specialized healthcare software becomes more valuable when integrated with comprehensive service platforms. IPS is described as “a market leading provider of practice management and EHR software to healthcare practices in chiropractic, optometry, speech and other therapy markets,” creating recurring revenue streams while supporting broader healthcare delivery ecosystems.

The firm’s healthcare IT investments consistently focus on platforms that become essential infrastructure for healthcare delivery, suggesting clinical trial software achieves optimal positioning when integrated with comprehensive research service offerings.

Building Platforms, Not Products

Reeve Waud’s healthcare platform investments undertake “over 10 add-on acquisitions” during the hold period on average, reflecting systematic approach to building comprehensive service ecosystems rather than standalone companies. This buy-and-build strategy has produced “an average revenue growth of 400%+” for realized healthcare investments.

Clinical trial platforms benefit from similar consolidation strategies, combining specialized research services with enabling technology to create comprehensive solutions for pharmaceutical companies. The fragmented nature of clinical research—with separate vendors for patient recruitment, data collection, regulatory submission, and site management—creates substantial consolidation opportunities for operators with Reeve Waud’s systematic platform-building expertise.

The ecosystem approach provides competitive advantages that standalone clinical trial software companies cannot achieve, creating the sustainable market positions that generate superior private equity returns across healthcare technology investments.